Enasidenib is an oral medication used in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML). It is a targeted therapy that inhibits the isocitrate dehydrogenase 2 (IDH2) enzyme. This enzyme plays a crucial role in cellular metabolism and its mutation is implicated in the pathogenesis of AML.
